期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

IGF-1R调控乳腺癌细胞增殖和迁移的信号转导通路研究 被引量：1

Effects of IGF-1R on Growth and Migration of Breast Cancer Cell
下载PDF
导出
摘要 目的：使用小分子抑制物LY294002和PD98059分别抑制磷脂酰肌醇-3激酶（ PI3K）通路和有丝分裂活化蛋白激酶（MAPK）通路的信号转导，给予胰岛素样生长因子-1（IGF-1）刺激，检测乳腺癌细胞的增殖和迁移能力的变化。方法使用CCK-8法和体外迁移实验分别检测IGF-1干预下细胞的增殖能力，并以信号通路抑制剂处理后细胞作为对照组，同样使用CCK-8法和体外迁移实验检测其增殖能力。结果 IGF-1干预第2～4天，不同浓度IGF-1（20，50，100mg/L）均显著促进MDA-MB-231细胞增殖，与对照组比较，差异有统计学意义（P＜0．05）；当IGF-1浓度为50mg/L时促进作用最明显；使用LY294002（25μM）或PD98059（50μM）分别阻断PI3K通路和MAPK通路后，不仅抑制MDA-MB-231细胞基础水平的增殖，而且抑制IGF-1刺激下的细胞增殖能力，与DMSO对照组比较，差异有统计学意义（P＜0．01）；在不同浓度IGF-1（20，50，100mg/L）作用下，MDA-MB-231细胞迁移能力均增强，与对照组比较，差异有统计学意义（ P＜0．01）。结论 IGF-1干预后MDA-MB-231细胞的增殖和迁移能力明显增强，PI3K通路和MAPK通路均参与了IGF-1促进乳腺癌细胞增殖和迁移的信号转导。 Objective To investigate the effects of insulin-like growth factor receptor（IGF-1R） silencing on the role of phosphatidylinositol 3-kinase （ PI3K） and mitogen-activated protein kinase （ MAPK） pathway in insulin-like growth factor （ IGF）-1 induced cell growth and migration .Methods Protein kinase inhibitors LY294002 and PD98059 were used to inhibit PI3K and MAPK pathway in vitro respectively ,and cell growth and migration induced by IGF-1 were measured.Results IGF-1R shRNA effectively inhibited proliferation and migration capacity of MDA-MB-231 cells when compared to control shRNA group .Both LY294002 and PD98059 significantly reduced the cell growth and migration in-duced by IGF-1.Conclusion PI3K and MAPK pathways play an important part in cell growth and migration induced by IGF-1 .
作者 王会东 王阳 张军 张家鑫 王凯
机构地区 潍坊市人民医院乳腺外科
出处 《潍坊医学院学报》 2014年第3期195-198,共4页 Acta Academiae Medicinae Weifang
关键词 胰岛素样生长因子-1受体 磷脂酰肌醇-3激酶通路 有丝分裂活化蛋白激酶通路 乳腺肿瘤 Insulin-like growth factor receptor Phosphatidylinositol 3-kinase pathways Mitogen-activated protein kinase pathway Breast neoplasm
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献14

  • 1魏小勇,黎才海,饶荣生.p38 MAPK信号通路与肿瘤的关系[J].实用癌症杂志,2009,24(1):101-103. 被引量：21
  • 2Sachdev D.Regulation of breast cancer metastasis by IGF signaling [J].J Mammary Gland Biol Neoplasia,2008,13(4):431-441.
  • 3Crean JK,Finlay D,Murphy M,et al.The role of p42/44 MAPK and protein kinase B in connective tissue growth factor induced extracellular matrix protein production,cell migration,and actin cytoskeletal rearrangement in human mesangialcells [J].J Biol Chem,2002,277(46):44187-44194.
  • 4Guvakova MA,Boettiger D,Adams JC.Induction of fascin spikes in breast cancer cells hy activation of the insulin-like growth factor-Ⅰ receptor [J].Int J Biochem Cell Biol,2002,34(6):685-698.
  • 5Renehan AG,Zwahlen M,Minder C,et al.Insulin-like growth factor(IGF)-Ⅰ,IGF binding protein-3,and cancer risk,systematic review and meta-regression analysis [J].Lancet,2004,363:1346-1353.
  • 6Lann D,LeRoith D.The role of endocrine insulin-like growth factor-Ⅰ and insulin in breast cancer [J].J Mammary Gland Bioi Neoplasia,2008,13(4):371-379.
  • 7de Ostrovich KK,Lambertz I,Colby JK,et al.Paracrine verexpression of insulin-like growth factor-Ⅰ enhances mammary tumorigenesis in vive[J].Am J Pathol,2008,173(3):824-834.
  • 8Taunk NK,Goyal S,Moran MS,et al.Prognostic significance of IGF-1 Rexpression in patients treated with breast-conserving surgery and radiation therapy [J].Radiother Oncol,2010,96(2):204-208.
  • 9Casa AJ,Dearth RK,Litzenburger BC,et al.The type Ⅰ insulin-like growth factor receptor pathway:a key player in cancer therapeutic resistance[J].Front Biosci,2008,13:3273-3287.
  • 10Chang F,Lee JT,Navolanic PM,et al.Involvement of PI3K/Akt pathway in cell cycle progression,apoptosis,and neoplastic transformation:a target for cancer chemotherapy [J].Leukemia,2003,17(3):590-603.

二级参考文献18

  • 1李莉,高平进,沈伟利,刘建军,朱鼎良.血管紧张素Ⅱ诱导自发性高血压大鼠血管外膜成纤维细胞迁移活性涉及P38 MAPK[J].中华心血管病杂志,2005,33(6):557-560. 被引量：11
  • 2张斌,杜冠华.NSAIDs抗炎作用机制研究进展[J].中国药理学通报,2005,21(8):905-910. 被引量：18
  • 3Kanamoto T, Mota M,Takeda K,et al. Role of apoptosis signal-regulating kinase in regulation of the c-Jun N-terminal kinase pathway and apoptosis in sympathetic neurous [ J ]. Mol Cell Biol, 2000,20 ( 1 ) : 196.
  • 4Lee JC,Kumar S,Griswold DE,et al. Inhibition of p38MAP kinase as a therapeutic strategy[ J]. Immunopharmacology ,2000,47 ( 2 ) : 185.
  • 5Underwood DC,ariswold DE. Inhibition of p38 MAP kinase[ J]. Prog Respir Res,2000,8:342.
  • 6Ferrer I, Friguls B, Dalfo E, et al. Early modifications in the expression of mitogen activated protein kinase (MAPK/ERK), stress activated kinases SAPK/JNK and p38, and their phosphorylated substrates following focal cerebral ischemia [ J ]. Acta Neuropathol, 2003,105 (5) :425.
  • 7Obata T, Brown GE, Yaffe MB. MAP kinase pathways activated by stress : the p38 MAPK pathway [J]. C rit Care Med,2000,28 (4) :67.
  • 8Ravanti L,Toriseva M Penttinen R,et al. Expression of human collagenase-3 (MMP-13)by fetal skin fibroblasts is induced by transforming growth factor beta via p38mitogen - activated protein kinase [J]. FASEB J,2001,15(6) :1098.
  • 9Wen-Horng Wang, Ronald L, Hullinger, et al. Hepatitis B virus X protein via the p38MAPK pathway induces E2F1 release and ATR kinase activation mediating p53 apoptosis [J]. J Biol Chem, 2008,187 ( 7 ) : 147.
  • 10Kim MS, Lee EJ, Kim HR, et al. p38 kinase is a key signaling molecule for H-ras-induced cell motility and invasive phenotype in human breast epithelial cel[J]. Dancer Res,2003,63 ( 17 ) :5454.

共引文献20

同被引文献66

  • 1Torre IrA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J].CA: ACancerJ Clin,2015,65(2):87-108.
  • 2Baldo P, Fornasier G, Francescon S, et al. Toxicities and ad verse drug reactions experienced during anticancer treatment it is desirable to consider the problem within the international system of pharmacovigilanee[J]. J Clin Oncol,2015,33(25) :28242825.
  • 3de Azambuja E, Ameye L, Diaz M, et al. Cardiac assessment of early breast cancer patients 18 years after treatment with cyclo phosphamide-, methotrexate-, fluorouracil-or epirubicin-based chemotherapy[J]. Eur J Cancer,2015,51(17) :2517-2524.
  • 4Danese MD, Masaquel A, Santos E, et al. Estimated Life-Years Saved in Women with HER2 Positive Metastatic Breast Cancer Receiving First lane Trastuzumab and Pertuzumab in the United States[J]. Value Health, 2015,18(6):876-883.
  • 5Mitsiades CS, Mitsiades NS, Mcmullan CJ, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematolog ic malignancies, and solid tumors[J].Cancer Cell, 2004,5 (3) : 221-230.
  • 6Tian J, Berton TR, Shirley SH termines estrogen receptor alpha et al. Developmental stage de expression and non-genomic mechanisms that control IGF-1 signaling and mammary prolift ra tionin mice[J]. j ClinInvest,2012,122(1):192-204.
  • 7Li LQ, Li XL, Wang I., et al. Matrine inhibits breast cancer growth via miR 21/PTEN/Akt pathway in MCF 7 cells[J]. Cell Physiol Biochem,2012,30(3) :631-641.
  • 8Zhong Z, Dang Y, Yuan X, et al. Furanodiene, a natural prod uct, inhibits breast cancer growth both in vitro and in vivo[J]. Cell Physiol Biochem,2012,30(3) :778-790.
  • 9Rajput S, Kumar/3N, Sarkar S, et al. Targeted apoptodc effects of thymoquinone and tamoxifen on XIAP mediated Akt regulation in breast cancer[J/CD]. PLoS One,2013,8(4) :e61342.
  • 10Hiraga T, Myoui A, Hashimoto N, et al. Bone-derived IGF me diates crosstalk between bone and breast cancer cells in bony metastasesEJ3. Cancer Res,2012,72(16) :42384249.

引证文献1

二级引证文献12

潍坊医学院学报
2014年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部